SCHEMBL7106203

SCHEMBL7106203

C=CCNC(=O)c1nc2ccccc2[nH]1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FAAH O00519 11/20 0.53
▸ TP53 P04637 1/20 0.52
▸ L3MBTL1 Q9Y468 1/20 0.52
▸ HDAC3 O15379 2/20 0.49
▸ HDAC1 Q13547 2/20 0.49
▸ HDAC2 Q92769 2/20 0.49
▸ CNR2 P34972 1/20 0.49
▸ USP30 Q70CQ3 1/20 0.48
▸ SMYD3 Q9H7B4 1/20 0.48
▸ KDM4E B2RXH2 1/20 0.47
▸ ALDH1A1 P00352 1/20 0.47
▸ POLB P06746 1/20 0.47
▸ MAPT P10636 1/20 0.47
▸ IDO1 P14902 1/20 0.47
▸ AURKA O14965 1/20 0.46
▸ JAK2 O60674 1/20 0.46
▸ ABL1 P00519 1/20 0.46
▸ NTRK1 P04629 1/20 0.46
▸ LCK P06239 1/20 0.46
▸ FYN P06241 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9703646 0.82 HPGD (0.53) TP53L3MBTL1KDM4EALDH1A1POLB
SCHEMBL24450206 0.81 HDAC3 (0.58) FAAHHDAC3HDAC1HDAC2CNR2
SCHEMBL4069991 0.79 LMNA (0.57) FAAHHDAC3HDAC1HDAC2CNR2
SCHEMBL4307360 0.79 EGLN1 (0.67) FAAHHDAC3HDAC1HDAC2CNR2
SCHEMBL7423976 0.79 SMYD3 (0.58) FAAHHDAC3HDAC1HDAC2CNR2
SCHEMBL6016962 0.78 HDAC2 (0.65) FAAHTP53L3MBTL1HDAC3HDAC1
SCHEMBL28377716 0.78 HDAC3 (0.65) FAAHHDAC3HDAC1HDAC2CNR2
SCHEMBL4954498 0.78 FAAH (0.51) FAAHHDAC3HDAC1HDAC2CNR2
SCHEMBL10045194 0.77 HDAC3 (0.52) FAAHHDAC3HDAC1HDAC2CNR2
SCHEMBL10454736 0.77 TP53 (0.43) TP53L3MBTL1KDM4EALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1206265-B1 SRC KINASE INHIBITOR COMPOUNDS MERCK & CO INC (US) 2003-11-12 — — EP disclosed
US-6498165-B1 PYRIMIDINE COMPOUNDS; PROPHYLAXIS AND TREATMENT OF SUCH AS IMMUNE DISEASES, HYPERPROLIFERATIVE DISORDERS, CANCER, ANGIOGENSIS, ATHEROSCELEROSIS, GRAFT REJECTION, RHEUMATOID ARTHRITIS, PSORIASIS MERCK & CO., INC. 2002-12-24 — — US disclosed
EP-1194152-A4 SRC KINASE INHIBITOR COMPOUNDS MERCK & CO INC (US) 2002-11-06 — — EP disclosed
EP-1206260-A4 SRC KINASE INHIBITOR COMPOUNDS MERCK & CO INC (US) 2002-10-30 — — EP disclosed
EP-1206260-A1 SRC KINASE INHIBITOR COMPOUNDS Merck & Co., Inc. (US) 2002-05-22 — — EP disclosed
EP-1194152-A1 SRC KINASE INHIBITOR COMPOUNDS Merck & Co., Inc. (US) 2002-04-10 — — EP disclosed
US-6329380-B1 PYRIMIDINE BENZIMIDIZAZOLE, PYRIMIDINEIMIDAZOLE OR PYRIDINE IMIDAZOLE COMPOUNDS FOR ANTICANCER AGENTS OR ATHEROSCLEROSIS MERCK & CO., INC. 2001-12-11 — — US disclosed
US-6316444-B1 SRC kinase inhibitor compounds MERCK & CO., INC. 2001-11-13 — — US disclosed
WO-2001000214-A1 SRC KINASE INHIBITOR COMPOUNDS MERCK & CO., INC. (US) 2001-01-04 — — WO disclosed
WO-2001000207-A1 SRC KINASE INHIBITOR COMPOUNDS MERCK & CO., INC. (US) 2001-01-04 — — WO disclosed
Send feedback